Barely Significant
← all excerpts

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.

Cardiovasc Diabetol · 2021 · PMC8571004 · PMID 34740359

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)
It showed a trend toward worse cardiac outcomes in the diabetic subgroup after liraglutide administration (HR = 1.54, p = 0.07), while there was no significant difference in the number of deaths or re-hospitalizations for HF in individuals without diabetes between the liraglutide group and the placebo group (HR = 1.02, p = 0.94) [ 147 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.